Provider Briefing: Anakinra Access in 2026

As a prescriber, few things are more frustrating than writing a clinically appropriate prescription only to have your patient call back days later saying they can't get it. For Anakinra (Kineret), this scenario plays out more often than it should — not because of a supply failure, but because of the structural challenges inherent in specialty biologic distribution.

This briefing covers the current state of Anakinra availability, the prescribing implications, and the practical tools you can use to help your patients get their medication without unnecessary delays.

Supply Timeline and Current Status

Anakinra has had a generally stable supply history. Unlike some specialty biologics that have experienced manufacturing disruptions, Kineret is not currently listed on the FDA Drug Shortage database as of early 2026. The sole manufacturer, Swedish Orphan Biovitrum (Sobi), has maintained consistent production.

That said, Anakinra's distribution model creates practical access barriers that can mimic shortage conditions at the patient level:

• Single-source manufacturing: Sobi is the only manufacturer. There are no approved biosimilars or generic alternatives, creating a single point of failure in the supply chain.
• Specialty pharmacy distribution: Kineret is dispensed almost exclusively through specialty pharmacy channels. Standard retail pharmacies do not routinely stock it.
• Cold chain requirements: The product requires continuous refrigeration (2°C to 8°C), limiting which distributors and pharmacies can handle it.

While these factors don't constitute a shortage, they do mean that patient-facing access can be inconsistent, particularly for new starts or when transitioning between pharmacies.

Prescribing Implications

Anakinra remains an important option in several clinical scenarios where IL-1 blockade is indicated:

FDA-Approved Indications

• Rheumatoid arthritis: Moderately to severely active RA in adults who have failed ≥1 DMARD. Current ACR guidelines have deprioritized anakinra for RA in favor of TNF inhibitors and other biologics, but it remains an option for patients who fail or are intolerant to these agents.
• NOMID/CAPS: A cornerstone of treatment for neonatal-onset multisystem inflammatory disease and other cryopyrin-associated periodic syndromes.
• DIRA: The primary treatment for deficiency of interleukin-1 receptor antagonist.

Off-Label Uses with Clinical Support

• Adult-Onset Still's Disease (AOSD): Strong evidence supports IL-1 blockade; anakinra is widely used.
• Recurrent pericarditis: Anakinra has demonstrated efficacy in clinical trials, though rilonacept (Arcalyst) now has FDA approval specifically for this indication.
• Acute gout flares: Particularly useful in patients who cannot tolerate NSAIDs, colchicine, or corticosteroids.
• Familial Mediterranean Fever (FMF): Used in colchicine-resistant patients.
• Macrophage activation syndrome (MAS): Anakinra's rapid onset and short half-life make it advantageous in acute inflammatory crises.

Key Prescribing Considerations

• Do not combine with TNF inhibitors — increased serious infection risk with no additional benefit (etanercept + anakinra studies showed higher infection rates)
• Avoid live vaccines during treatment
• Monitor neutrophil counts: ANC monthly for 3 months, then quarterly for up to 1 year
• Renal dosing: Consider every-other-day dosing for patients with CrCl <30 mL/min
• Screen for infections: Including latent TB, before initiation

The Availability Picture

When patients report difficulty finding Anakinra, the issue typically falls into one of three categories:

1. Pharmacy Channel Mismatch

The most common issue. Patients present their prescription at a retail pharmacy that doesn't stock biologics. Solution: Route prescriptions directly to a specialty pharmacy. Many practices maintain standing relationships with specialty pharmacies for exactly this reason.

2. Insurance Authorization Gaps

Prior authorization and step therapy requirements create a window where the patient has a prescription but no approved coverage. This is particularly problematic for new starts. Solution: Initiate the PA process concurrent with — or even before — writing the prescription. Sobi's Bridge and QuickStart programs can provide interim supply.

3. Refill Timing Gaps

Specialty pharmacy refills require more lead time than standard prescriptions. Patients who wait until their last syringe often face gaps. Solution: Educate patients to initiate refills at least 7-10 days before their supply runs out.

Cost and Access Landscape

Cost remains a significant barrier for many patients:

• Wholesale Acquisition Cost (WAC): Approximately $1,549 for a 7-syringe (1-week) supply
• Estimated monthly cost (cash): $6,200+
• Per-syringe cost: $203-$424 depending on pharmacy and channel

Available Support Programs

Contact Sobi's support line at 866-547-0644 to enroll patients in any manufacturer program.

Tools and Resources for Your Practice

Medfinder for Providers — Search pharmacy availability and help patients locate Anakinra in stock. This tool can save your staff significant time that would otherwise be spent calling pharmacies.

Additional resources:

• How to help your patients find Anakinra in stock: A provider's guide
• How to help patients save money on Anakinra: Provider's guide
• Anakinra drug interactions: What to avoid

Looking Ahead

The IL-1 inhibitor landscape is relatively mature. No anakinra biosimilars are on the near-term horizon, and the competitive set — canakinumab (Ilaris) and rilonacept (Arcalyst) — has been stable. Rilonacept's FDA approval for recurrent pericarditis in 2021 has shifted some prescribing away from off-label anakinra for that indication, but anakinra remains the preferred choice in many acute and autoinflammatory settings due to its rapid onset and short half-life.

For patients with CAPS, NOMID, DIRA, and AOSD, Anakinra continues to be a critical therapy. Ensuring these patients have uninterrupted access should be a priority.

Final Thoughts

Anakinra is not in shortage — but the specialty pharmacy infrastructure through which it's distributed creates real access friction. As prescribers, the most impactful steps you can take are:

1. Route prescriptions directly to specialty pharmacies
2. Start prior authorization early — before patients run out
3. Enroll eligible patients in manufacturer support programs proactively
4. Use tools like Medfinder for Providers to check pharmacy stock
5. Educate patients on specialty pharmacy refill timelines

Your patients depend on this medication. A few proactive steps in your workflow can prevent most access disruptions before they happen.